Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

229 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and Safety of a Botanical Formula Fuzheng Huayu for Hepatic Fibrosis in Patients with CHC: Results of a Phase 2 Clinical Trial.
Hassanein T, Tai D, Liu C, Box TD, Tong MJ, Rossaro L, Pozza R, Glenn JS, Cheung R, Hemaidan A, He Y, Behling C, Hu X, Makhlouf H, Fan H, Ren Y, Khim Chng EL, Liu P, Vierling JM. Hassanein T, et al. Evid Based Complement Alternat Med. 2022 Jul 15;2022:4494099. doi: 10.1155/2022/4494099. eCollection 2022. Evid Based Complement Alternat Med. 2022. PMID: 35873630 Free PMC article.
Hepatitis C infection: Updates on treatment guidelines.
Pozza R, Hill C, Hefner AM, Vawter B, Hassanein T. Pozza R, et al. Among authors: hassanein t. Nurse Pract. 2017 May 12;42(5):14-23. doi: 10.1097/01.NPR.0000515423.38284.28. Nurse Pract. 2017. PMID: 28379888 Review.
Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials.
Lawitz E, Buti M, Vierling JM, Almasio PL, Bruno S, Ruane PJ, Hassanein TI, Muellhaupt B, Pearlman B, Jancoriene L, Gao W, Huang HC, Shepherd A, Tannenbaum B, Fernsler D, Li JJ, Grandhi A, Liu H, Su FH, Wan S, Dutko FJ, Nguyen BT, Wahl J, Robertson MN, Barr E, Yeh WW, Plank RM, Butterton JR, Yoshida EM. Lawitz E, et al. Among authors: hassanein ti. Lancet Gastroenterol Hepatol. 2017 Nov;2(11):814-823. doi: 10.1016/S2468-1253(17)30163-2. Epub 2017 Aug 10. Lancet Gastroenterol Hepatol. 2017. PMID: 28802814 Clinical Trial.
Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir in Patients With Hepatitis C Virus Genotype 1 or 4 Infection and Advanced Kidney Disease.
Lawitz E, Gane E, Cohen E, Vierling J, Agarwal K, Hassanein T, Mantry PS, Pockros PJ, Bennett M, Kemmer N, Morelli G, Zha J, Wang D, Shulman NS, Cohen DE, Reddy KR. Lawitz E, et al. Among authors: hassanein t. Kidney Int Rep. 2018 Oct 9;4(2):257-266. doi: 10.1016/j.ekir.2018.10.003. eCollection 2019 Feb. Kidney Int Rep. 2018. PMID: 30775622 Free PMC article.
Eradicating hepatitis C virus: The APRN's role.
Pozza R, McCoy-Hill C, Hall K, Hefner A, Wilgers K, Tapelband J, Masroor M, Hassanein T. Pozza R, et al. Among authors: hassanein t. Nurse Pract. 2019 Nov;44(11):16-27. doi: 10.1097/01.NPR.0000586008.23422.2c. Nurse Pract. 2019. PMID: 31567700
Clinical correlates of histopathology in pediatric nonalcoholic steatohepatitis.
Patton HM, Lavine JE, Van Natta ML, Schwimmer JB, Kleiner D, Molleston J; Nonalcoholic Steatohepatitis Clinical Research Network. Patton HM, et al. Gastroenterology. 2008 Dec;135(6):1961-1971.e2. doi: 10.1053/j.gastro.2008.08.050. Epub 2008 Sep 3. Gastroenterology. 2008. PMID: 19013463 Free PMC article. Clinical Trial.
229 results